This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Q2 revenue rises 28%, profit turns positive; H1 profit Rs 3.42 crore
LYKALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.4 pts less than Nifty Microcap 250 and 2.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Q2 FY27 standalone revenue rose 28.3% year on year to Rs 42.31 crore; profit after tax was Rs 1.32 crore versus a Rs 3.62 crore loss. H1 revenue rose 39.2% to Rs 86.51 crore and profit after tax reached Rs 3.42 crore against a Rs 2.81 crore loss. The auditor's review found no material misstatement. Figures were restated after Lyka Export merged into Lyka Labs. The FY26 comparison includes a Rs 33.24 crore net exceptional charge.
Strong sales growth and a return to profit support sentiment, though merger-related restatement and the prior-year loss limit clean comparisons.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹44.20 Cr | ₹36.66 Cr | +20.6% |
| Operating profit | ₹0.45 Cr | −₹5.48 Cr | turned positive |
| Profit after tax | ₹1.27 Cr | −₹3.21 Cr | turned positive |
| EBITDA margin | 8.0% | -6.9% | +14.9 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.